Greenwich Wealth Management LLC Buys New Shares in Novo Nordisk A/S $NVO

Greenwich Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,800 shares of the company’s stock, valued at approximately $331,000.

A number of other large investors have also recently bought and sold shares of the business. Lockheed Martin Investment Management Co. lifted its stake in Novo Nordisk A/S by 179.4% during the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock valued at $2,999,000 after acquiring an additional 27,900 shares in the last quarter. Unified Investment Management purchased a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $692,000. Acadian Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 15,919.9% during the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock valued at $72,523,000 after purchasing an additional 1,038,137 shares in the last quarter. Guild Investment Management Inc. boosted its holdings in Novo Nordisk A/S by 20.7% during the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock worth $2,553,000 after purchasing an additional 6,345 shares during the last quarter. Finally, Norden Group LLC boosted its holdings in Novo Nordisk A/S by 216.3% during the second quarter. Norden Group LLC now owns 96,332 shares of the company’s stock worth $6,649,000 after purchasing an additional 65,877 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $49.35 on Monday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The stock has a fifty day simple moving average of $52.81 and a two-hundred day simple moving average of $59.66. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $112.52. The firm has a market cap of $220.33 billion, a price-to-earnings ratio of 13.56, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on NVO. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, November 24th. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. HSBC downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, The Goldman Sachs Group lowered their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.83.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.